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The emergence of multidrug-resistant Pseudomonas aeruginosa has become a
serious problem in medical settings. P. aeruginosa clinical isolate PA7 is resistant
to fluoroquinolones, aminoglycosides, and most β-lactams but not imipenem. In this
study, enhanced efflux-mediated fluoroquinolone resistance of PA7 was shown to reflect
increased expression of two resistance nodulation cell division (RND) -type multidrug
efflux operons, mexEF-oprN and mexXY-oprA. Such a clinical isolate has rarely been
reported because MexEF-OprN-overproducing mutants often increase susceptibility to
aminoglycosides apparently owing to impairment of the MexXY system. A mutant of
PA7 lacking three RND-type multidrug efflux operons (mexAB-oprM, mexEF-oprN, and
mexXY-oprA) was susceptible to all anti-pseudomonas agents we tested, supporting an
idea that these RND-type multidrug efflux transporters are molecular targets to overcome
multidrug resistance in P. aeruginosa. mexEF-oprN-upregulation in P. aeruginosa PA7 was
shown due to a MexS variant harboring the Valine-155 amino acid residue. This is the
first genetic evidence shown that a MexS variant causes mexEF-oprN-upregulation in
P. aeruginosa clinical isolates.
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INTRODUCTION
Pseudomonas aeruginosa is a metabolically versatile bacterium
that can cause a wide range of severe opportunistic infections in
patients with serious underlying medical conditions (Gellatly and
Hancock, 2013). Infections caused by P. aeruginosa often are hard
to treat; inappropriate chemotherapy readily selects multidrug-
resistant P. aeruginosa against which very few agents are effective
(Morita et al., 2014; Poole, 2014). This so-called “antibiotic resis-
tance crisis” has been compounded by the lagging in antibiotic
discovery and development programs occurred in recent years,
and is jeopardizing the essential role played by antibiotics in cur-
rent medical practices (Rossolini et al., 2014). To combat this
organism, it is very useful to understand its antimicrobial resis-
tance mechanisms (see reviews such as Breidenstein et al., 2011;
Poole, 2011; Morita et al., 2015).
The complete genome sequence of the multiresistant P. aerugi-
nosa PA7 has been determined (Roy et al., 2010). The sequence of
this strain, which exhibits resistance to fluoroquinolones (FQs),
aminoglycosides, and various β-lactams but is susceptible to car-
bapenems (imipenem), includes typical FQ-resistance mutations
in gyrA (Thr83Ile) and parC (Ser87Leu) (Roy et al., 2010). PA7
has additionally acquired a mutated aacA4 gene, the product
of which (AAC(6′)-II) endows the strain with aminoglycoside
(gentamicin and tobramycin) resistance (Roy et al., 2010). This
clinical isolate is amenable to the construction of gene knock-out
mutations, thereby facilitating the analysis of molecular mech-
anisms of multidrug antimicrobial resistance in this isolate.
Previously we showed that the effect of the modifying enzyme
is enhanced by the MexXY resistance nodulation cell division
(RND) -type multidrug efflux system, especially in the presence
of divalent cations, providing high-level aminoglycoside resis-
tance in P. aeruginosa (Morita et al., 2012b). This observation
emphasizes the importance of theMexXYmultidrug efflux system
for aminoglycoside resistance in multidrug-resistant P. aeruginosa
clinical isolates (Morita et al., 2012a).
Four members of the RND family of multidrug efflux sys-
tems, MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY
have been implicated in FQ resistance in P. aeruginosa clini-
cal isolates (Poole, 2011). As in other organisms, these RND
family drug efflux transporters in P. aeruginosa operates as
three-component pumps with an RND cytoplasmic membrane
(CM) protein (MexB, MexD, MexF, and MexY) linked to an
outer membrane channel-forming protein (OprM, OprJ, and
OprN) by a CM-tethered periplasmic protein (MexA, MexC,
MexE, and MexX) (Poole, 2013). Intriguingly PA7 possesses the
mexXY-oprA multidrug efflux operon of which oprA is missing
in most P. aeruginosa strains (Roy et al., 2010). We showed that
the MexXY can utilize either the OprA or OprM as an outer
membrane component of the tripartite efflux pump (Morita
et al., 2012b). Multidrug-resistant P. aeruginosa clinical isolates,
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including carbapenem-resistant P. aeruginosa, often have been
reported to be MexXY and/or MexAB-OprM overproducers (e.g.,
Hocquet et al., 2007; Cabot et al., 2011; Fuste et al., 2013;
Khuntayaporn et al., 2013; Vatcheva-Dobrevska et al., 2013).
FQ efflux is mediated by the MexAB-OprM system constitu-
tively produced at moderate levels in wild-type P. aeruginosa
PAO1 (Morita et al., 2001; Poole, 2013). Expression of mexAB-
oprM is controlled directly or indirectly by three repressors
encoded by the mexR, nalC and nalD genes, with inactivat-
ing mutations in any of these resulting in increased mexAB-
oprM expression (Poole, 2011, 2013). In addition, nfxB and
nfxC mutants (which overproduce components of the MexCD-
OprJ and MexEF-OprN systems, respectively) are well-known
as efflux-mediated FQ-resistant mutants of laboratory and clin-
ical isolates of P. aeruginosa, although nfxB mutations appear
to be rare in clinical settings (Poole, 2011). nfxC mutants also
show increased resistance to carbapenems such as imipenem, not
because MexEF-OprN accommodates these agents but because
of a coordinated, MexT-dependent reduction of OprD produc-
tion in such mutants (Poole, 2011, 2013). Hyperexpression of
mexEF-orpN (and reduction in oprD expression) is also seen in
laboratory isolates disrupted in the mexS gene, which encodes a
putative oxidoreductase (a.k.a qrh) of unknown function (Sobel
et al., 2005; Lamarche and Deziel, 2011). There are, however, no
reports (to our knowledge) with experimental evidence ofmexEF-
oprN-expressing clinical isolates harboring mutations in mexS
(Poole, 2013), although some studies suggested possible muta-
tion of mexS in nfxC-type clinical isolates (e.g., Llanes et al.,
2011; Fournier et al., 2013). The incidence of MexXY overpro-
ducers among clinical isolates has shown to be linked to the use
of ciprofloxacin (Hocquet et al., 2008) and MexXY overproduc-
ers have been often reported to be one of major phenotypes in
multidrug resistant clinical isolates (Morita et al., 2012a; Poole,
2013). However, MexXY-expressing FQ-resistance or its contri-
bution to FQ-resistance in clinical settings has not well been
studied compared to the other three pumps. In this study, we
used reverse genetics to investigate the role of efflux-mediated
FQ resistance in multidrug-resistant P. aeruginosa clinical
isolate PA7.
MATERIALS AND METHODS
BACTERIAL STRAINS, PLASMIDS, AND GROWTH CONDITIONS
The bacterial strains and plasmids used in this study are listed
in Table 1. Bacterial cells were grown in Luria (L) broth and on
L agar (1.5%) under aerobic conditions at 37◦C as previously
described, unless otherwise indicated, with antibiotics as neces-
sary (Morita et al., 2010). Bacterial growth was quantified by
measuring the optical density at 600 nm on an Ultrospec 2100 Pro
Spectrophotometer (GE Healthcare Corp., Tokyo, Japan), unless
otherwise indicated. The plasmids pEX18Tc (Hoang et al., 1998),
pYM101 (Morita et al., 2010), and their derivatives were main-
tained and selected using medium supplemented with 2.5-10μg
tetracycline ml−1 for E. coli or 50–150μg tetracycline ml−1 for
P. aeruginosa. The plasmids pUCP20T (Schweizer et al., 1996) and
pFLP2 (Hoang et al., 1998) and their derivatives were maintained
and selected using medium supplemented with 100μg ampicillin
ml−1 for E. coli or 200μg carbenicillin ml−1 for P. aeruginosa.
Table 1 | Bacterial strains and plasmids.
Strains or
plasmids
Relevant characteristics References
E. COLI
DH5α
(PAGUg121)
For recombinant DNA manipulation Morita et al., 2010
KAM3
(PAGUg846)
For recombinant DNA manipulation Morita et al., 1998
S17-1
(PAGUg856)
For conjugational transfer Morita et al., 2006
P. AERUGINOSA
PAO1 (PAGU
974)
Wild type Morita et al., 2006
PA7 (PAGU
1498)
Multi-resistant clinical isolate Roy et al., 2010
PAGUg1565 PA7 mexXY-oprA Morita et al., 2012b
PAGUg1603 PA7 mexAB-oprM Morita et al., 2012b
PAGUg1748 PA7 mexEF-oprN This study
PAGUg1641 PA7 mexXY-oprA mexAB-oprM Morita et al., 2012b
PAGUg1751 PA7 mexXY-oprA mexEF-oprN This study
PAGUg1753 PA7 mexAB-oprM mexEF-oprN This study
PAGUg1756 PA7 mexXY-oprA mexAB-oprM
mexEF-oprN
This study
PAGUg1793 PA7 mexS This study
PAGUg1789 PA7 mexT This study
PAGUg1867 PA7 mexS(V155A) This study
DSM 1128
(PAGU 1504)
Taxonomically PA7-related strain,
wild-type
Kiewitz and
Tummler, 2000
K2153 (PAGU
1741)
Clinical isolate Sobel et al., 2003
K2376
(PAGUg1834)
K2153 mexS Fetar et al., 2011
PAGUg1850 K2153 mexS attB::lacIq-PT7 This study
PAGUg1851 K2153 mexS
attB::lacIq-PT7-mexSPA7
This study
PAGUg1844 K2153 mexS
attB::lacIq-PT7-mexSDSM 1128
This study
PAGUg1854 K2153 mexS pUCP20T This study
PAGUg1855 K2153 mexS pUCP20T::mexSPA7 This study
PAGUg1856 K2153 mexS
pUCP20T::mexSDSM 1128
This study
PAGUg1835 K2153 mexT Fetar et al., 2011
PAGUg1836 K2153 mexF Fetar et al., 2011
K2942
(PAGUg1837)
K2153 mexS mexT Fetar et al., 2011
PAGUg1852 K2153 mexS mexT
attB::lacIq-PT7
This study
PAGUg1846 K2153 mexS mexT
attB::lacIq-PT7-mexTPA7
This study
PAGUg1845 K2153 mexS mexT
attB::lacIq-PT7-mexTDSM 1128
This study
PLASMID
pEX18Tc Broad-host-range gene
replacement vector
Hoang et al., 1998
pYM133 pEX18Tc::mexEF-oprN This study
pYM134 pEX18Tc::mexS This study
(Continued)
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Table 1 | Continued
Strains or
plasmids
Relevant characteristics References
pYM135 pEX18Tc::mexT This study
pYM136 pEX18Tc::mexST This study
pYM137 pEX18Tc::mexSPA7 This study
pYM138 pEX18Tc::mexSPA7(V155A) This study
pYM101 P. aeruginosa chromosome
integration vector
Morita et al., 2010
pYM139 pYM101::mexSPA7 This study
pYM140 pYM101::mexSDSM 1128 This study
pYM141 pYM101::mexTPA7 This study
pYM142 pYM101::mexTDSM 1128 This study
pUCP20T Broad-host-range cloning vector Schweizer et al.,
1996
pYM143 pUCP20T::mexSPA7 This study
pYM144 pUCP20T::mexSDSM 1128 This study
pFLP2 Flp recombinase-producing plasmid Hoang et al., 1998
MOLECULAR BIOLOGY TECHNIQUES
Plasmid DNA isolation from E. coli, DNA purification, measur-
ing DNA concentration, DNA digestion with restriction enzymes,
DNA dephosphorylation, DNA ligation, isolation of chromo-
somal DNA from P. aeruginosa, PCR conditions, nucleotide
sequencing, competent cell preparation from E. coli, transfor-
mation of E. coli, and transfer of plasmids into P. aeruginosa
via conjugation were performed as described previously (Morita
et al., 2010), unless otherwise indicated. DNA sequences and
amino acid sequences were analyzed through 2012 to 2013 with
Pseudomonas Genome Database (Winsor et al., 2011), Basic
Local Alignment Search Tool (BLAST) (Boratyn et al., 2013),
SWISS-MODEL (Bordoli et al., 2009), Sorting Tolerant From
Intolerant (SIFT) BLink (Kumar et al., 2009), and the software
DNASIS Pro (Ver. 2.1; Hitachi, Japan).
CLONING OF mexS AND mexT FROM P. AERUGINOSA
mexS and mexT from P. aeruginosa (without endogenous pro-
moters) were amplified by PCR using the primers listed in
Table 2. The purified mexS PCR product, digested with BamHI
and HindIII, was cloned into similarly digested, dephospho-
rylated pUCP20T and pYM101, yielding pUCP20T::mexS and
pYM101::mexS. The purified mexT PCR product, digested with
EcoRI and BamHI, was cloned into similarly digested, dephos-
phorylated pUCP20T and pYM101, yielding pUCP20T::mexT
and pYM101::mexT.
CONSTRUCTION OF IN-FRAME DELETION MUTANTS FROM
P. AERUGINOSA
In-frame deletion mutants ofmexEF-oprN,mexS, andmexT from
P. aeruginosa PA7 and its derivatives were constructed using the
previously described sacB-based strategy (Morita et al., 2006,
2010). The plasmids and resulting P. aeruginosa mutants are
listed in Table 1, while the primer pairs are listed in Table 2.
The selection concentrations of tetracycline for the first homolo-
gous recombination event were adjusted to reflect the endogenous
tetracycline MICs for the P. aeruginosa strains. These constructs
were confirmed by colony PCR.
CONSTRUCTION OF THECTX-BASED SITE-SPECIFIC INTEGRANTS IN
P. AERUGINOSA
For gene complementation experiments in P. aeruginosa, CTX
phage-based site-specific integrants were constructed using
the integration-proficient, tightly controlled expression vec-
tor pYM101 and associated techniques (conjugative transfer,
gene replacement at the chromosomal attB site, and curing
of the unwanted plasmid backbone from the chromosome via
the pFLP2-encoded Flp recombinase) as previously described
(Morita et al., 2010).
SITE-DIRECTED MUTAGENESIS OF mexSPA7 IN THE CHROMOSOME OF
P. AERUGINOSA PA7
An amino acid substitution (Val155Ala) mutation was intro-
duced into the mexSPA7 gene of the insert in the plasmid
pUC20T::mexSPA7. Site-directed mutagenesis within a target plas-
mid was carried out according to Geiser et al. (2001) and Morita
et al. (2009). A 50-μl mixture consisting of 50 ng of plasmid DNA,
0.25μM of each mutagenic primer pair (Table 2), 0.2mM each
deoxynucleoside triphosphate, 1mM MgSO4, 2.5 U of KOD Hot
Start DNA polymerase -Plus- Ver.2 (TOYOBO Co. Ltd., Osaka,
Japan), 1× KOD buffer, and 4.0% (vol/vol) dimethyl sulfoxide
was heated to 94◦C for 2min followed by 18 cycles of 0.5min
at 94◦C, 1min at 60◦C, and 5min at 68◦C. The resulting DNA
products were purified as above, digested overnight with 10 U
DpnI (Roche Diagnostics K.K., Tokyo, Japan) to eliminate tem-
plate plasmid), and used to transform E. coli DH5α. Plasmids
were recovered from individual transformants, and the mexS
insert was sequenced to identify plasmids bearing the desired
mutation. The mexS insert carrying the mutation was digested
with BamHI and HindIII and cloned into similarly digested and
dephosphorylated pEX18Tc to yield pEX18Tc::mexSPA7(V155A).
ThemexSPA7(V155A)mutation was gene replaced onto the chro-
mosome of P. aeruginosa PA7 using the previously described
sacB-based strategy (Morita et al., 2009, 2012b).
ANTIBIOTIC SUSCEPTIBILITY ASSAY
The susceptibility of P. aeruginosa to antimicrobial agents in
cation-adjusted Mueller–Hinton broth was assessed using the
2-fold serial microtiter broth dilution method described previ-
ously (Morita et al., 2012b). Minimal inhibitory concentrations
(MICs) were defined as the lowest concentration of antibiotic
resulting in visible inhibition of growth after 18 h of incubation
at 37◦C. MICs for the CTX-based site-specific integrants were
determined in the presence of the inducer 5mM isopropyl-β-D-
1-thiogalactopyranoside (IPTG). The categorization in suscepti-
ble, intermediate, and resistant was performed according to the
interpretive standards of the Clinical and Laboratory Standards
Institute (CLSI) (Patel et al., 2011).
ANTIMICROBIAL AGENTS
Amikacin, ampicillin, carbenicillin, chloramphenicol,
ciprofloxacin, norfloxacin, and tetracycline were purchased
from Wako Pure Chemicals Industries, Ltd (Osaka, Japan).
Moxifloxacin and levofloxacin were purchased from LKT
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Table 2 | Primers used in this study.
Primer Sequence(5′–3′) Purpose References
EcoRI-mexEPA7-UF GAT CGA ATT CTG GCC TCG GGG GAA ATC T mexEF-oprN genes disruption of P. aeruginosa
PA7
This study
BamHI-mexEPA7-UR CTG AGG ATC CAT GCT TGA CTC CGC CAG TC mexEF-oprN genes disruption of P. aeruginosa
PA7
This study
BamHI-oprNPA7-DF CTG AGG ATC CTG AAC CGG CTA TCC CCG G mexEF-oprN genes disruption of P. aeruginosa
PA7
This study
XhoI-oprNPA7-DR GAT CCT CGA GCG CCG ACA GCG ATT GCC A mexEF-oprN genes disruption of P. aeruginosa
PA7
This study
BamHI-mexSPA7-F GAT CGG ATC CGA TGC ACT GCA GAG GTT TGC mexS gene cloning of P. aeruginosa PA7 and
DSM 1128
This study
HindIII-mexSPA7-R CTA GAA GCT TCA ATC GGC GAC GTG GAT mexS gene cloning of P. aeruginosa PA7 and
DSM 1128
This study
EcoRI-mexSPA7-UF GCT AGA ATT CAG TTC GTC GGT GTA GCT GA mexS gene disruption of P. aeruginosa PA7 This study
BamHI-mexSPA7-UR CTA GGG ATC CGG ACA TCG CAA ACC TCT G mexS gene disruption of P. aeruginosa PA7 This study
BamHI-mexSPA7-DF GCT AGG ATC CGT CGC CGA TTG AGG ACG AC mexS gene disruption of P. aeruginosa PA7 This study
HindIII-mexSPA7-DR CTA GAA GCT TAG TAC ATC CAC GCG CAC CT mexS gene disruption of P. aeruginosa PA7 This study
EcoRI-mexTPA7-F GAT CGA ATT CCC CTG GAA ACG AGG AAC mexT gene cloning of P. aeruginosa PA7 and
DSM 1128
This study
BamHI-mexTPA7-R GAT CGG ATC CTC AGA GGC TGT CCG GGT C mexT gene cloning of P. aeruginosa PA7 and
DSM 1128
This study
SacI-mexTPA7-UF GCT AGA GCT CTG GAA ACG ATC ACC CGC G mexT gene disruption of P. aeruginosa PA7 This study
BamHI-mexTPA7-UR CTG AGG ATC CAT GGC GTT CCT CGT TTC C mexT gene disruption of P. aeruginosa PA7 This study
BamHI-mexTPA7-DF GCT AGG ATC CGG ACA GCC TCT GAG TCA TCC ACG mexT gene disruption of P. aeruginosa PA7 This study
HindIII-mexTPA7-DR CTA GAA GCT TGC GAC CGC CGC CCT GGC TT mexT gene disruption of P. aeruginosa PA7 This study
mexSPA7(V155A)-F CTG ATC ACC GAG GCG GCG CGC ATG TAC GGG CC mexS(V155A) site directed mutagenesis of
P. aeruginosa PA7
This study
mexSPA7(V155A)-R GGC CCG TAC ATG CGC GCC GCC TCG GTG ATC AG mexS(V155A) site directed mutagenesis of
P. aeruginosa PA7
This study
mexTS intergenic seq GCA CCA GGA CTT CCC CTG DNA sequencing of mexT-mexS intergenic
region
This study
uvrD-F ATCGACTTCTCCGAGCTGCTG RT-PCR for uvrD gene of P. aeruginosa Morita et al., 2012b
uvrD-R CTGGAACTCGTCCACCAGGAT RT-PCR for uvrD gene of P. aeruginosa Morita et al., 2012b
mexE-F (RT) CCA CCC TGA TCA AGG ACG AAG RT-PCR for mexE gene of P. aeruginosa This study
mexE-R (RT) CGG TAG ACG GTC TTG TTG TCG RT-PCR for mexE gene of P. aeruginosa This study
mexS-F (RT) AGG GCG TCA ATG TCA TCC TC RT-PCR for mexS gene of P. aeruginosa This study
mexS-R (RT) CTG CAG GTG CTT CTT GAA CG RT-PCR for mexS gene of P. aeruginosa This study
mexT -F (RT) TAT TGA TGC CGA ACC TGC TG RT-PCR for mexT gene of P. aeruginosa This study
mexT -R (RT) GGA GGA TCT TCG GCT TGC TG RT-PCR for mexT gene of P. aeruginosa This study
oprD-F (RT) ATT GCA CTG GCG GTT TCC RT-PCR for oprD gene of P. aeruginosa This study
oprD-R (RT) ATG AAC CCC TTC GCT TCG RT-PCR for oprD gene of P. aeruginosa This study
mexA-F (RT) GAC AAC GCT ATG CAA CGA ACG RT-PCR for mexA gene of P. aeruginosa This study
mexA-R (RT) AGC TCG GTA TTC AGC GTC ACC RT-PCR for mexA gene of P. aeruginosa This study
Laboratories, Inc. (St. Paul, MN, USA). Imipenem/cilastatin was
purchased from Sandoz K.K. (Tokyo, Japan).
REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTASE (qRT)-PCR
Overnight cultures of P. aeruginosa strains were diluted 1:100
in 10ml, incubated with vigorous shaking at 37◦C for 3–4 h,
and harvested. Total RNA was stabilized with the RNA Protect
Bacteria Reagent (Qiagen) and isolated with the RNeasy Mini
Kit (Qiagen). The RNA samples were further treated with RQ1
RNase-Free DNase (Promega) and purified by using the RNeasy
Mini Kit (Qiagen). Real-time qRT-PCR was performed with
primer pairs internal to uvrD, mexE, mexS, mexT, and oprD
(Table 2) using the One Step SYBR PrimeScript RT-PCR kit II
(TaKaRa) in a Thermal Cycler Dice real-time system (TaKaRa).
The transcript levels of the target gene in a given strain were nor-
malized to levels of uvrD and expressed as a ratio (fold change) to
that observed in the parental PA7 strain. Gene expression values
were calculated based on triplicate experiments.
NUCLEOTIDE SEQUENCE ACCESSION NUMBER
The nucleotide sequences of DNA regions containing mexT
and mexS in P. aeruginosa DSM 1128 have been deposited
in GenBank/EMBL/DDBJ with the accession number
AB889539.
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RESULTS
CONTRIBUTION OF RND MULTIDRUG EFFLUX SYSTEMS TO FQ
RESISTANCE IN P. AERUGINOSA PA7
FQ resistance in P. aeruginosa PA7 was compared with the two
FQ-susceptible strains, PAO1 (the standard laboratory strain) and
DSM 1128 (a strain taxonomically related to PA7) (Morita et al.,
2012b). The MICs of the FQs (ciprofloxacin, levofloxacin, moxi-
floxacin, and norfloxacin) for P. aeruginosa PA7, PAO1, and DSM
1128 are shown in Table 3. P. aeruginosa PA7 exhibited increased
resistance (ca. 256-fold) to these FQs compared to P. aerugi-
nosa PAO1 and DSM 1128. P. aeruginosa DSM 1128 showed the
same level of resistance to the FQs as P. aeruginosa PAO1. Based
on the interpretive standards of the CLSI (Patel et al., 2011),
P. aeruginosa PA7 was considered highly resistant to these FQs.
This observation is not surprising, because P. aeruginosa PA7 pos-
sesses typical target mutations, one in gyrA (Thr83Ile) and one
in parC (Ser87Leu), well-known to be associated with FQ resis-
tance (Lomovskaya et al., 1999). However, target mutations alone
are not sufficient to explain high-level FQ resistance in P. aerugi-
nosa; the additional effect of up-regulation of one of the four RND
efflux pumps (MexXY-OprA, MexAB-OprM, MexCD-OprJ, or
MexEF-OprN) is necessary (Lomovskaya et al., 1999; Bruchmann
et al., 2013).
Previously we showed that the mexXY-oprA mexAB-oprM
double mutant of PA7 was slightly more susceptible (ca. 2-
to 4-fold) to ciprofloxacin, while retaining high-level resistance
(MIC = 32μg/ml) to this antibiotic when compared to its
parental strain (Morita et al., 2012b). That observation was incon-
sistent with data, derived via similar genetic analyses, in which
a PAO1-derived oprM gyrA parC triple mutant (i.e., a strain
deleted for oprM and carrying the target mutations) exhibited
increased susceptibility (64-fold) to levofloxacin compared to
an isogenic MexAB-OprM overexpressing (nalB) mutant, while
exhibiting an MIC (0.5μg/ml) of levofloxacin similar to that of
the wild-type PAO1 (0.25μg/ml) (Lomovskaya et al., 1999). We
noted that deletion of oprM in PAO1 was expected to inactivate
any efflux pumps that require OprM as an outer membrane fac-
tor (e.g., MexAB-OprM,MexXY-OprM,MexVW-OprM) (Morita
et al., 2001; Li et al., 2003). We therefore hypothesized that
overexpression of other RND pumps such as MexCD-OprJ and
MexEF-OprN was compensating for the effects of the mexAB-
oprM mexXY-oprA double deficiency in PA7. As a first step in
testing our hypothesis, we examined the primary sequences of the
efflux system-encoding genes of PA7. Sequence analysis revealed
the presence of mexCD-oprJ (PSPA7_0540- 0539- 0538) and
mexEF-oprN (PSPA7_2745-2744-2743) homologs in P. aerugi-
nosa PA7 (Roy et al., 2010), with predicted amino acid lengths
(in PA7) and amino acid sequence identity and similarity [respec-
tively; via BLAST of PA7 vs. PAO1-UW (Winsor et al., 2011)]
as follows: MexC (387 aa; 88 and 95%), MexD (1043 aa; 95 and
98%,), OprJ (475 aa; 89 and 93%); MexE (414 aa; 99 and 99%),
MexF (1062 aa; 99 and 99%), and OprN (472 aa; 97 and 99%).
As a second step in testing our hypothesis, we examined the
regulation of these genes in PA7. qRT-PCR showed that expres-
sion of mexE was increased (ca. 22-fold) in PA7 compared to
the wild-type strain DSM 1128. This observation indicated that
FQ resistance in P. aeruginosa can be mediated by overexpres-
sion of the mexEF-oprN operon, in addition to the previously
reported overexpression of mexXY-oprA due to mutation of the
local repressor gene (mexZ) (Morita et al., 2012b).
We also observed that a mexXY-oprA mexAB-oprM
mexEF-oprN triple mutant derived from PA7 exhibited
increased susceptibility to FQs (32–128-fold) compared to an
isogenic mexXY-oprA mexAB-oprM double mutant, while
exhibiting only mild elevation of FQ MIC (0.5–2μg/ml) com-
pared to wild-type PAO1 and DSM 1128 (0.125–1μg/ml)
(Table 3). Moreover, the triple mutant was much more sensitive
(512-fold) to chloramphenicol than the double mutant, a further
indicator ofMexEF-OprN-mediated resistance (Sobel et al., 2005)
(Table 3). We excluded a role for overexpression of mexCD-oprJ
in PA7, as judged by the susceptibilities of the mutant (mexXY-
oprA mexAB-oprM mexEF-oprN construct) to not only FQs
but also to tetracycline and chloramphenicol, which are substrates
of MexCD-OprJ (Poole et al., 1996).
To clarify the roles of MexXY-OprA, MexAB-OprM and
MexEF-OprN multidrug efflux pumps in the FQ resistance of
P. aeruginosa PA7, we constructed a series of deletion mutants
of the three mex operons and examined their drug susceptibility
Table 3 | Contribution of three RND efflux pumps to antimicrobial resistance of P. aeruginosa PA7.
Strain Genotype MIC (µg/ml) of
CIP NOR LVX MXF AMK CHL IPM
PA7 (PAGU 1498) Parent 64 128 128 256 32 1024 2
PAGUg1565 PA7 mexXY-oprA 32 64 64 128 1 1024 2
PAGUg1603 PA7 mexAB-oprM 64 128 64 256 32 1024 2
PAGUg1748 PA7 mexEF-oprN 32 64 64 256 32 128 2
PAGUg1641 PA7 mexXY-oprA mexAB-oprM 32 64 32 64 1 1024 2
PAGUg1751 PA7 mexXY-oprA mexEF-oprN 8 16 8 32 1 256 2
PAGUg1753 PA7 mexAB-oprM mexEF-oprN 32 64 32 128 32 16 2
PAGUg1756 PA7 mexXY-oprA mexAB-oprM mexEF-oprN 0.5 0.5 0.5 2 1 4 2
DSM 1128 (PAGU 1504) Wild type 0.125 0.25 0.25 1 0.5 32 1
PAO1 (PAGU 974) Wild type 0.125 0.25 0.25 1 0.5 32 1
AMK, amikacin; CHL, chloramphenicol; CIP, ciprofloxacin; IPM, imipenem; LVX, levofloxacin; MXF, moxifloxacin; NOR, norfloxacin.
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profiles (Table 3). We observed that the mexXY-oprA mexEF-
oprN double deletion mutant was more susceptible (4-fold)
than the mexAB-oprM mexXY-oprA double mutant and the
mexAB-oprM mexEF-oprN double mutant (Table 3). These
data suggested that the MexXY-OprA and MexEF-OprN systems
make similar contributions to FQ resistance in P. aeruginosa PA7,
each having an effect larger than that of MexAB-OprM. The
apparent modest MexAB-OprM contribution to resistance of FQs
and chloramphenicol in PA7 [PA7 mexXY-oprA mexEF-oprN
vs. PA7 mexXY-oprA mexAB-oprM mexEF-oprN (Table 3)]
is typically observed in wild type P. aeruginosa such as PAO1
already shown in the previous results (e.g., PAO1 mexXY vs.
PAO1mexXY mexAB-oprM) (e.g., Morita et al., 2001), imply-
ing that mexAB-oprM is expressed at moderate levels in PA7. We
concluded that high-level FQ resistance in P. aerguinosa PA7 was
due to overproduction of MexXY-OprA and MexEF-OprN, in
addition to the typical target mutations.
MOLECULAR MECHANISMS OF mexEF-oprN-UPREGULATION IN
P. AERUGINOSA PA7
The mexEF-oprN operon is quiescent in wild-type P. aeruginosa
cells grown under standard laboratory conditions. In contrast,
this operon is expressed in so-called nfxCmutants and inmutants
defective in themexS gene (previously known as qrh), a locus that
encodes a putative oxidoreductase of as yet unknown function
(Poole, 2013). Expression of mexEF-oprN is regulated by a tran-
scriptional activator, MexT, a LysR family regulator (Kohler et al.,
1999; Poole, 2013). mexT occurs upstream of mexEF-oprN and
downstream of mexS, the latter gene also positively regulated by
MexT (Kohler et al., 1999). Unusually, many so-called wild type
strains possess inactiveMexT (e.g., 8 bp insertion inmexT present
in some PAO1 strains) (Maseda et al., 2000; Poole, 2013). The
induction of mexEF-oprN contributes to multidrug resistance,
albeit against a rather narrow range of antimicrobials includ-
ing FQs, trimethoprim, and chloramphenicol (Poole, 2013). The
enhanced resistance to imipenem of nfxC mutants or mexS defi-
cient mutants results not from mexEF-oprN expression but the
concomitant decrease in the level of outer membrane protein
OprD (Poole, 2013), because OprD is an imipenem channel and
serves as the primary route of entry of this antibiotic in P. aerug-
inosa (Trias and Nikaido, 1990). However, P. aeruginosa PA7 was
reported to be susceptible to carbapenems, with MICs of 2 and
1μg/ml for imipenem and meropenem, respectively (Roy et al.,
2010). This observation of carbapenem susceptibility is somewhat
paradoxical, given that a typical nfxC mutant or a mexS defi-
cient mutant is expected to exhibit carbapenem resistance due
to a coordinate, MexT-dependent reduction of OprD levels. We
found that P. aeruginosa PA7 exhibited slight but reproducible ele-
vation (2-fold) of resistance to imipenem compared to wild-type
P. aeruginosa strains PAO1 and DSM 1128 (Table 4). Deletion of
mexS in a PA7 background resulted in slightly increased expres-
sion of mexE (2-fold) and increased resistance to imipenem
(4-fold) compared to PA7. Thus, PA7 appeared to exhibit sus-
ceptibility intermediate between that of wild type and a typical
nfxC mutant. Deletion of mexT in a PA7 background resulted in
drastically (>200-fold) decreased expression of mexE and mexS
compared to PA7 (Table 4). Notably, expression of mexS in PA7
mexT was more than 96-fold reduced compared to the wild-
type DSM 1128 and PA7 mexS (V155A). This observation was
consistent with a previous report (using β-galacotosidase reporter
assays) indicating that mexS (qrh) is constitutively expressed at a
moderate level (Kohler et al., 1999; Poole, 2013).
We therefore determined the nucleotide sequences (ca. 2.4 kb)
upstream of the mexEF-oprN operon in P. aeruginosa DSM
1128 (accession no. AB889539). This interval corresponds to the
operon’s cognate regulatory region, and includes the mexS and
mexT loci. Comparison to the corresponding sequences from
P. aeruginosa PA7 (data not shown) revealed that MexSPA7 is
encoded as an A155V variant, and MexTPA7 as an A256T vari-
ant, compared to the DSM 1128 genome. In contrast, alanine-155
of MexS and alanine-256 of MexT are conserved among multiple
laboratory and clinical strains, including PAO1, PA14, PAK, and
K2153 (Sobel et al., 2005; Jin et al., 2011; Lamarche and Deziel,
2011). To test the function of the mexSPA7 and mexTPA7 loci, we
amplified and cloned the individualmexS andmexT genes (with-
out endogenous promoters) from P. aeruginosa PA7 and DSM
1128, and expressed the relevant genes in P. aeruginosa K2153
mexS (Fetar et al., 2011) for amexS complementation test or in
K2153 mexS mexT (Sobel et al., 2005; Fetar et al., 2011) for a
mexT complementaton test (Table 5). [As demonstrated by other
researchers, P. aeruginosa K2153 and its derivatives are useful for
the analysis of mexEF-oprN-dependent antimicrobial resistance
as regulated by the MexT activator and MexS function (Sobel
et al., 2005; Fetar et al., 2011)]. Interestingly, introduction of
mexSDSM 1128 ormexSPA7 into the chromosome of K2153 mexS
did not provide complementation ofmexS (Table 5). These data
Table 4 | Relationship between antimicrobial resistance and mexS-mexT -mediated mexEF-oprN expression in P. aeruginosa.
Strains Genotype MIC (µg/ml) of Relative mRNA level
CIP CHL IPM mexE mexS mexT
PA7 (PAGU 1498) Parent 128 1024 2 1 1 1
PAGUg1793 PA7 mexS >128 >1024 8 2.0 nd 0.84
PAGUg1867 PA7 mexS(V155A) 64 256 1 0.053 0.57 0.74
PAGUg1789 PA7 mexT 64 128 1 < 0.005 < 0.005 nd
DSM 1128 (PAGU 1504) Wild type 0.125 32 1 0.046 0.48 1.1
PAO1 (PAGU 974) Wild type 0.125 32 1 nd nd nd
CHL, chloramphenicol; CIP, ciprofloxacin; IPM, imipenem; nd, not done.
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Table 5 | Functional characterization of mexS and mexT from
P. aeruginosa PA7 and DSM 1128.
Strains Genotype MIC (µg/ml)
CIP CHL IPM
K2153 (PAGU 1741) Parent 0.5 64 2
K2376 (PAGUg1834) mexS 2 2048 8
PAGUg1850 mexS attB::lacIq-PT7 2 2048 8
PAGUg1851 mexS attB::lacIq-PT7-mexSPA7 2 2048 8
PAGUg1844 mexS
attB::lacIq-PT7-mexSDSM 1128
2 1024 8
PAGUg1854 mexS pUCP20T 2 2048 8
PAGUg1855 mexS pUCP20T::mexSPA7 1 256 4
PAGUg1856 mexS
pUCP20T::mexSDSM 1128
0.5 64 2
K2942 (PAGUg1837) DmexS mexT 0.5 64 2
PAGUg1852 mexS mexT attB::lacIq-PT7 0.5 64 2
PAGUg1846 mexS mexT
attB::lacIq-PT7-mexTPA7
2 2048 8
PAGUg1845 mexS mexT
attB::lacIq-PT7-mexTDSM 1128
2 2048 8
CHL, chloramphenicol; CIP, ciprofloxacin; IPM, imipenem.
5 mM IPTG was added to allow expression controlled by the PT7 promoter.
contrast previous instances in which we observed attB-site (i.e.,
single-copy) complementation for several other genes (Morita
et al., 2010, 2012b). Presumably, in the present studies, failure
to complement reflected insufficient mexS expression from the
PT7 promoter in PAGUg1844, given thatMexSDSM 1128 is expected
to be functional. Introduction of pUCP20T::mexSDSM 1228 into
P. aeruginosa K2153mexS yieldedMICs identical to those of the
K2153mexS+ parent; introduction of pUCP20T::mexSPA7 yielded
parent-like resistance to imipenem, but only partially restored
resistance to ciprofloxacin and chloramphenicol (Table 5). Taken
together, these results suggested that MexSPA7 provides reduced
function compared to MexSDSM 1228. Additionally it appears that
the high levels of mexS expression are required to overcome the
nfxC-type antimicrobial resistance.
Slightly increased expression ofmexSwas observed in P. aerug-
inosa PA7 compared to P. aeruginosa DSM 1128 (ca. 2-fold),
while expression levels of mexT in P. aeruginosa PA7 were simi-
lar to those in P. aeruginosa DSM 1128 (c.a. 0.9-fold) (Table 4).
Introduction of mexTDSM 1128 or mexTPA7 into the chromosome
of K2153 mexS mexT yielded the nfxC phenotype (Table 5),
suggesting that the A256T substitution in MexT is not a pri-
mary reason for overexpression of mexEF-oprN in P. aeruginosa
PA7. Using site-specific mutagenesis, we altered the plasmid-
borne mexSPA7 locus to encode a V155A version of the protein
and replaced the endogenous PA7 chromosomal locus with the
mutated gene. The PA7mexSPA7(V155A) strain showed decreased
mexE expression (0.053-fold compared to that of the PA7 parent),
a value similar to that seen in DSM 1128 (0.034-fold com-
pared to that of PA7) (Table 4). The PA7 mexSPA7(V155A) strain
also showed decreased MICs for chloramphenicol (0.25-fold)
(Table 4). Taken together with the complementation experi-
ments, these data strongly suggested that the A155V substitution
in MexSPA7 is the primary reason for increased expression of
mexEF-oprN and increased antimicrobial resistance in the PA7
strain.
DISCUSSION
In this study, the multidrug-resistant clinical isolate PA7 was
shown to exhibit increased expression of mexEF-oprN as well
as mexXY-oprA. Although multidrug-resistant P. aeruginosa clin-
ical isolates have often been reported to be MexXY overpro-
ducers (Morita et al., 2012a), clinical strains of P. aeruginosa
overproducing MexEF-OprN and MexXY(-OprA) efflux pumps
simultaneously have rarely been reported. In fact, PA7 was not
a typical nfxC mutant (i.e., a MexEF-OprN overproducer), and
instead expressed intermediate levels of mexEF-oprN. We assume
that simultaneous overproduction of MexEF-OprN andMexXY(-
OprA) impairs P. aeruginosa growth, based on our observation
that our PA7 mexS construct (i.e., a simultaneous overpro-
ducer of MexEF-OprN and MexXY-OprA compared to the PA7
parent) was unstable even on L agar plates: colonies of the con-
struct exhibited a non-uniform phenotype during growth on
plates (data not shown). This observation is consistent with the
increased susceptibility to aminoglycosides previously observed
in MexEF-OprN-overproducing nfxC mutants, apparently owing
to impairment of the MexXY system (Sobel et al., 2005).
Valine-155 of MexSPA7 also was shown as the likely primary
reason for increased production of MexEF-OprN in PA7. With
the exception of mexSPA7, sequenced P. aeruginosa mexS genes
(including those from PAO1, K2153, PA14, PAK, and DSM 1128)
encode proteins with an alanine at residue 155 (Sobel et al., 2005;
Jin et al., 2011; Lamarche and Deziel, 2011). The Ala155Val sub-
stitution is predicted by the SIFT algorithm (Kumar et al., 2009)
not to affect the protein’s function (data not shown). We hypoth-
esize that MexSPA7 retains function, albeit with decreased activity
and/or altered regulation (e.g., allostery), compared with the
other MexS orthologs. In fact, there were few differences among
the whole structures of MexSPA7, MexSPAO1, and MexSDSM 1128
models developed by using the SWISS-MODEL program (data
not shown) (Bordoli et al., 2009). MexS is a member of the
cd08268: MDR2 family of the Conserved Domains Database
(CDD) of the National Center for Biotechnology Information
(NCBI) (Fargier et al., 2012) and alanine-155 corresponds to
one of the putative NAD(P) binding sites featured in the MDR2
family.
In addition to antibiotic resistance, an nfxC-type mutation has
been linked to reduced levels of homoserine lactone-dependent
quorum sensing (QS) -regulated virulence factors, including
pyocyanin, elastase, rhamnolipids, and Pseudomonas Quinolone
Signal (PQS), and to reduced expression of type-III secretion sys-
tem (TTSS) effector proteins (Kohler et al., 2001; Linares et al.,
2005). QS is a cell-to-cell communication mechanism employing
diffusible signal molecules (Jimenez et al., 2012), and the TTSS
is a mechanism by which bacterial pathogens can deliver effec-
tors directly into the cytoplasm of eukaryotic host cells (Hauser,
2009).We found that PA7 had reduced level of pyocyanin produc-
tion, rhamnolipid production, and swarming activity compared
to DSM 1128 and PAO1 (data not shown), consistent with the
typical nfxC mutant phenotype (Jin et al., 2011). However, PA7
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derivatives including PA7 mexSPA7(V155A) also showed almost
the same activities of the QS regulated virulence factors with
PA7 (data not shown), which suggests that the impaired QS-
related phenotype is not derived from the nfxC-like phenotype in
PA7. We presume that this lack of correlation reflects the absence
from PA7 of TTSS-encoding genes and of the mvfR (pqsR) gene,
which is known to encode a LysR-type transcriptional regulator
that modulates the expression of multiple QS-regulated virulence
factors (Deziel et al., 2005; Roy et al., 2010). These deficien-
cies might be the source of the mexS mutation and increased
mexEF-oprN expression under oxidative stress, sulfide stress, or
nitrosative stress (Juhas et al., 2004; Fetar et al., 2011; Fargier et al.,
2012).
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